TY - JOUR
T1 - Brain Metastases from Ovarian Cancer
T2 - Current Evidence in Diagnosis, Treatment, and Prognosis
AU - Borella, Fulvio
AU - Bertero, Luca
AU - Morrone, Antonio
AU - Gambella, Alessandro
AU - Bovetti, Marialuisa
AU - Cosma, Stefano
AU - Carosso, Andrea
AU - Katsaros, Dionyssios
AU - Gemmiti, Silvia
AU - Preti, Mario
AU - Valabrega, Giorgio
AU - Scotto, Giulia
AU - Cassoni, Paola
AU - Benedetto, Chiara
PY - 2020/8/4
Y1 - 2020/8/4
N2 - With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. BRCA1 and BRCA2 gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.
AB - With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. BRCA1 and BRCA2 gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.
U2 - 10.3390/cancers12082156
DO - 10.3390/cancers12082156
M3 - Review article
C2 - 32759682
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 8
ER -